Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
- Conditions
- Childhood EpendymoblastomaChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial Ependymoma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00052780
- Locations
- 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 500
- Registration Number
- NCT00052455
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00049387
- Locations
- 🇺🇸
Adult Brain Tumor Consortium, Baltimore, Maryland, United States
Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT00005812
- Locations
- 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005637
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005955
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT00005952
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide in Treating Patients With Brain Metastases
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005954
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005815
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00027742
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.